All In Biotech

Drug Trial Radar · NCT07110571

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

A Multi-cohort, Multi-center Phase II Clinical Study of Adebrelimab in Combination With SHR-A1811/SHR-A1904 and Chemotherapy or Adebrelimab in Combination With SHR-8068 as the Treatment in Subjects With Gastric or Gastroesophageal Junction Cancer

Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Aug 28, 2025

Primary completion

Aug 2026

Study completion May 2027

Sponsor

Sponsor type
Industry
First posted
Aug 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-cohort, multi-center Phase II clinical study exploring the efficacy of treatment with either Adebrelimab plus SHR-A1811/SHR-A1904 and chemotherapy, or Adebrelimab plus SHR-8068 in patients with gastric or gastroesophageal junction (GEJ) cancer. The study also evaluates the safety and tolerability of these combination regimens.

Conditions

  • Gastric Cancer
  • Gastroesophageal-junction Cancer

Interventions

  • Adebrelimab InjectionDrug

    Adebrelimab injection.

  • SHR-A1811 for InjectionDrug

    SHR-A1811 for injection.

  • SHR-A1904 for InjectionDrug

    SHR-A1904 for injection.

  • SHR-8068 InjectionDrug

    SHR-8068 injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological complete response (pCR) rate assessed by the Pathology Review Committee (PRC).Time frame: Approximately 13 weeks.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.